NCT06397846 Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
| NCT ID | NCT06397846 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Condition | Benign Pancreatic Lesion |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-11 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-12-11 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The challenge for medical oncology is to develop plasma biomarkers that can detect the influence of the stroma on diagnosis, prognosis and response to chemotherapy. Today, there is no validated blood test to help diagnose pancreatic cancer (PDAC). The search for blood biomarkers of the tumor stroma and immunological markers is therefore a major challenge in orienting the diagnosis towards PDAC and optimizing the therapeutic management of pancreatic cancers. The aim of the study is to identify biomarkers associated with the presence of malignant pancreatic lesions (patients from the Pancreas-CGE cohort, a cohort already set up by our team) compared with benign lesions (patients followed up for benign pancreatic lesions). Candidate biomarkers from our preliminary work will be considered initially. Other biomarkers may be explored secondarily. The ultimate goal is to develop a clinico-biological signature that is as efficient as possible in predicting the presence of malignant pancreatic lesions compared with benign ones.
Eligibility Criteria
Inclusion Criteria: * Men and women ≥18 years * Patient followed for benign pancreatic lesions: chronic pancreatitis acute pancreatitis at a distance from the acute episode (\> 4 weeks) with indication for echo-endoscopy for suspected precancerous pancreatic lesions (PanIN, TIPMP, mucinous cystadenomas) or other cystic lesions (serous cystadenomas) Exclusion Criteria: * Malignant pancreatic tumor * Legal incapacity or limited legal capacity
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06397846 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Benign Pancreatic Lesion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06397846 currently recruiting?
Yes, NCT06397846 is actively recruiting participants. Contact the research team at a3vienot@chu-besancon.fr for enrollment information.
Where is the NCT06397846 trial being conducted?
This trial is being conducted at Besançon, France, Montbéliard, France.
Who is sponsoring the NCT06397846 clinical trial?
NCT06397846 is sponsored by Centre Hospitalier Universitaire de Besancon. The trial plans to enroll 100 participants.